BioSpace News Archive

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the approval of the next-generation Eversense® E3 CGM System by the Food and Drug Administration (FDA).

Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced that company management will participate in the following upcoming investor conferences:

Gilead Sciences, Inc. (Nasdaq: GILD) today released data demonstrating the in vitro activity of Veklury® (remdesivir) against ten SARS-CoV-2 variants, including Omicron.

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2021 financial results will be released after market close on Thursday, February 17, 2022.

Oxurion NV will be presenting data from Part A of its two-part Phase 2 Clinical Trial assessing THR-149 for treatment of diabetic macular edema at the upcoming Angiogenesis, Exudations, and Degeneration 2022 Meeting being held virtually on February 11-12th.

Lysogene, a phase 3 gene therapy platform company targeting central nervous system diseases, reports positive biomarker data from the ongoing AAVance clinical trial with LYS-SAF302 for the treatment of MPS IIIA as well as favorable safety data from the ongoing adaptative clinical trial with LYS-GM101 for the treatment of GM1 gangliosidosis.

During the fourth quarter 2021, Alligator reached several key milestones in our pre-clinical, clinical, and partnered programs.

Biotage has managed to deal with the global challenges in the supply chain and ended 2021 with another sales record in the fourth quarter.

Humanigen, Inc. announced that Timothy E. Morris, COO/CFO, will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.

Akari Therapeutics, Plc announced that Clive Richardson, Chief Executive Officer of Akari Therapeutics, will present a company overview during the BIO CEO & Investor Conference on Tuesday, February 15, 2022 at 2:30 p.m. ET, at the New York Marriott Marquis.